Clinical Trials Browser

Phase 1/2 × Lymphoma, Mantle-Cell × ofatumumab × Clear all

NCT01221103 2011-09-13

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell